<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02109315</url>
  </required_header>
  <id_info>
    <org_study_id>DIAB-01</org_study_id>
    <nct_id>NCT02109315</nct_id>
  </id_info>
  <brief_title>Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.</brief_title>
  <acronym>DIAB-01</acronym>
  <official_title>Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Cruceta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of liraglutide on vascular injury induced hypoglycemia in patients
      with type 1 diabetes mellitus. The vascular damage is evaluated at investigating the changes
      of endothelial function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the effect of antioxidants (Vitamin C) on the vascular damage induced
      hypoglycemia in patients with type 1 diabetes. The vascular injury was evaluated in the same
      way as main objective. Checking the existence of a peripheral response to the action of GLP-1
      due to oxidative stress.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress markers</measure>
    <time_frame>8 weeks</time_frame>
    <description>Oxidative stress markers (nitrotyrosine and 8-iso prostaglandin F2 alpha plasma) in serum1 inflammation markers (serum sICAM-1, interleukin 6) 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Liraglutide endovenous 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide endovenous de 0.6 mg. one time a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamine C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamine C</intervention_name>
    <description>C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min</description>
    <arm_group_label>Vitamine C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 6 mg</intervention_name>
    <description>Liraglutide endovenous de 0.6 mg. one time a day</description>
    <arm_group_label>Liraglutide endovenous 6 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed and signed consent obtained before any trial-related activity . (
             Trial-related activities are those procedures that were not performed during routine
             medical examination of the patient) .

          -  Diagnosis of type 1 diabetes.

          -  Patients who do not have autonomic dysfunction , defined by ( 1).

          -  Patients not showing episodes of hypoglycemia unawareness based on the methods of Gold
             et al (2) .

          -  Patients without microvascular complications of diabetes.

          -  Patients without macrovascular complications of diabetes.

          -  Patients treated with multiple daily injections of insulin.

          -  No smoking .

          -  They should have a complete blood count, lipid profile, liver profile , renal profile
             and plasma electrolyte levels within normal values .

          -  No subject must have a history of hypertension or taking medication for high blood
             pressure .

          -  No subject should be taking medications known to affect the neuroendocrine responses
             to hypoglycemia or anti inflammatory

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to study some related products.

          -  Fertile women, lactating or pregnant, intend to become pregnant or who are not using
             adequate contraception, or men who have sexually active and are not sterilized
             surgically, those whose partners are not using a method adequate contraception.

          -  Clinical diagnosis of Type 2 Diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Ceriello A Ceriello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital clínic i provincial de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

